



Original Article

Phenotyping and Genotyping Evaluation of *E. coli* Produces Carbapenemase Isolated from Cancer Patients in Al-Basrah, Iraq

Ali Albadery, A¹*, Shakir Mahdi Al-Amara, S¹, Abd-Al-Ridha Al-Abdullah, A²

1. Department of Biology, College of Science, University of Basrah, Basrah, Iraq
2. Department of Pathological analyses, College of Science, University of Basrah, Basrah, Iraq

Received 30 August 2022; Accepted 10 September 2022
Corresponding Author: aseelsweely@gmail.com

Abstract

One of the most important nosocomial organisms that cause urinary tract infections (UTIs) in cancer patients is *Escherichia coli*. A significant cause of concern in managing UTIs is the development of carbapenem-resistant bacteria. *Escherichia coli* with carbapenem resistance has become a more serious problem, particularly in Iraq. In this regard, the present study aimed to estimate the prevalence of carbapenem-resistant *E. coli* in Al-Basrah, Iraq. Conventional tests and the Vitek[®]2 system were used to identify the isolates and determine the susceptibility of *E. coli* isolates to antimicrobials. In addition, *E. coli* isolates were tested by mCIM and eCIM methods. Moreover, the major carbapenemase genes, including *bla_{SPM}*, *bla_{IMP}*, *bla_{VIM}*, and *bla_{KPC}* were detected by polymerase chain reaction. In total, 120 urine samples were collected from cancer patients who were suspected of having urinary tract infections at Basrah Center of Oncology Al-Sader Teaching Hospital, Basrah, Iraq. Identification of bacterial growth by using biochemical tests revealed different bacterial species. The most frequent bacteria were *E. coli* (n=22, 53.65%) isolates. The results showed that 13 (59.09%) and 11 (50%) out of 22 *E. coli* isolates were positive for the production of carbapenemase, based on the eCIM and sCIM, respectively. The majority of *E. coli* in this study possessed the *bla_{VIM}* gene (n=13, 59.1%), followed by the *bla_{KPC}* gene (n=5, 22.73%), *bla_{IMP}* gene (n=5, 22.73%), and *bla_{SPM}* gene (n=4, 18.18%). There is a spread of more than one type of carbapenemase among the *E. coli* isolates collected from UTI cancer patients in Basrah Hospital. The *E. coli* identified in the current study had a strong capacity to produce carbapenemase enzymes against the four generations of antibiotics, including imipenem and meropenem antibiotics.

Keywords: Cancer, Carbapenemase, *E. coli*, Urinary tract infections

1. Introduction

The immune system of cancer patients is compromised due to underlying malignancy, such as leukemia, as well as the harmful side effects of cancer treatment, such as chemotherapy, radiation, and bone marrow transplantation. This could result in prolonged immunosuppression, increasing the risk of infection and possibly worsening the prognosis (1).

Urinary tract infection (UTI) is one of the most prevalent infections in cancer patients (2). The UTI is identified as one of the most common microbial infections in humans, and in the community and healthcare organizations, its control and prevention is a significant health issue (3). Enterobacteriaceae is the most prevalent UTI, with uropathogenic *Escherichia coli* accounting for around 80-90% of all infections (4, 5).

The β -lactam class of antimicrobials, which includes carbapenems, is a broad-spectrum group of substances with a four-membered β -lactam ring. Carbapenems are commonly used and play a significant role in treating mixed aerobic and anaerobic infections, infections in immune-compromised patients, and infections caused by multiple drug-resistant bacterial strains (6, 7). The development of carbapenemases results in resistance to penicillins, cephalosporins, and carbapenems, which are only a few of the many hydrolyzable β -lactams that the flexible carbapenemase family can break down (8).

Carbapenem resistance is accompanied by a decrease in outer membrane permeability with increased expression of carbapenemase enzymes, simultaneous production of AmpC beta-lactamases, and extended-spectrum beta-lactamases (8). Due to the suppression of the immune system in cancer patients and the high prevalence of bacterial infections, antibiotic resistance is prevalent among them. In this research, the genotypes and phenotypic of isolated bacterial strains of *E. coli* were evaluated in cancer patients with urinary tract infections treated with carbapenems in Basrah Center of Oncology, Al-Sader Teaching Hospital, Basrah, Iraq.

2. Materials and Methods

2.1. Collection of Specimens

From October 2021 to January 2022, 120 urine samples were collected from cancer patients in Basrah Center of Oncology, Al-Sader Teaching Hospital, from patients within the age range of 18-84 years old who

were suspected of having urinary tract infections. It is noteworthy that 50 (41.7%) samples belonged to males and 70 (58.3%) samples belonged to females. After explaining the purpose of the study, written informed consent was obtained from the patients.

2.2. Isolation and Identification

Conventional tests identified all the *E. coli* isolates according to Forbes, Sahm (9) and Prescott and Harley (10). The first and the second steps, including the confirmed identification, were performed by the Vitek[®]2 system (bioMérieux, France).

2.3. Antibiotic Sensitivity Test

Carbapenem resistance was detected using Imipenem (10 μ g; Liofilchem Company) disc according to the method of Clinical and Laboratory Standards Institute CLSI (11) and Sfeir, Hayden (12). The Vitek[®]2system was used in the current study to detect and confirm the antibiotic susceptibility tests of *E. coli* isolates to detect the ability to produce carbapenemase.

2.4. Molecular Detection

2.4.1. DNA Extraction

DNA was extracted from a pure culture of *E. coli* bacteria using a DNA extraction bacteria kit (Geneaid). Afterward, DNA bands were detected using agarose gel electrophoresis (1%). The presence of the carbapenemases genes was determined using a gene-specific primer targeting *bla_{IMP}*, *bla_{VIM}*, *bla_{SPM}*, and *bla_{KPC}*. The primers were obtained from the Macrogen Company, Korea (Table 1).

Table 1. Specific primers of antibiotic-resistant genes of the carbapenemases

Primers	DNA Sequences (5'-3')	product Size bp	Reference
<i>bla_{SPM}</i>	F AAAATCTGGGTACGCAAACG	271	Shoja, Moosavian (13)
	R ACATTATCCGCTGGAACA		
<i>bla_{VIM}</i>	F GGTGTTTGGTCGCATATCGCAA	502	Shoja, Moosavian (13)
	R ATTACGCCAGATCGGCATCGGC		
<i>bla_{IMP}</i>	F TCGTTTGAAGAAGTTAACG	568	Shoja, Moosavian (13)
	R ATGTAAGTTTCAAGAGTGATGC		
<i>bla_{KPC}</i>	F CATTCAAGGGCTTTCTTGCTGC	498	Mushi, Mshana (14)
	R ACGACGGCATAGTCATTTGC		

2.4.2. Polymerase Chain Reaction Assay for the Detection of Carbapenemase Genes

polymerase chain reaction (PCR) was carried out in a total reaction volume of 25 μ l consisting of 1 μ l forward and 1 μ l the reverse primer for each gene. Moreover, 2 μ l of DNA template and 8.5 μ l of nuclease-free water were added to 12.5 μ l of PCR master mix (Promega, USA), and the thermal cycling machine (Bioneer, Korea) was programmed for DNA amplification. The program included an initial denaturation step at 95 °C for 5 min, denaturation and annealing at 94 °C and 60 °C, respectively for 45 seconds, and elongation for 1 min at 72 °C (35 cycles). The same program was used for *bla_{KPC}*, except the annealing temperature was adjusted to 55 °C for 45 s, and all primer sets had a final extension of 72 °C for 7 min (15).

2.5. Statistical Analysis

The statistical analysis was carried out in SPSS software (version 20.0). The collected data regarding group significance were evaluated using the Student's t-test. In the analysis, a *P* value of less than 0.05 was considered statistically significant.

3. Results

In total, 120 samples were collected from cancer patients in Basrah Center of Oncology Al-Sader Teaching Hospital, from patients within the age range of 18-84 years old who were suspected of having urinary tract infections. In terms of gender, 50 (41.7%)

samples belonged to males and 70 (58.3%) samples belonged to females. Based on the results, 41 (34.2%) out of 120 urine samples were positive urine cultures, while 79 (65.8%) samples were negative urine cultures.

Identification of bacterial growth by using biochemical tests revealed different bacterial species, the most frequent of which was *E. coli* (n=22, 53.65%). It should be mentioned that the other species were found in 19 isolates (46.34%). The results showed that 13 (59.09%) out of 22 *E. coli* isolates were positive for produced carbapenemase based on the eCIM. Moreover, 7 (31.82%) out of 22 *E. coli* isolates were positive for produced carbapenemase types class A+D while 6 (27.27%) isolates were positive for produced carbapenemase types class A+D and class B. However, 9 (40.91%) isolates were found to be negative for produced carbapenemase based on the EDTA-modified carbapenem inactivation method (eCIM) (Figure 1).

In total, 11 (50%) isolates were positive for produced carbapenemase enzymes according to the sCIM. In addition, 5 (22.73%) isolates yielded intermediate results for the produced carbapenemase enzymes. In contrast, 6 (27.27%) isolates were negative for the produced carbapenemase based on a simplified carbapenem inactivation method (sCIM) (Table 2).

The majority of *E. coli* isolates in the current study possessed the *bla_{vim}* gene (n=13, 59.1%) followed by the *bla_{KPC}* gene (n=5, 22.73%), *bla_{IMP}* gene (n=5, 22.73%), and *bla_{SPM}* gene (n=4, 18.18%) (Figures 2-5).








Figure 1. The *E. coli* isolates positive and negative results for produced carbapenemase types class A+D and B

Table 2. The results of produced carbapenemase by using the simplified carbapenem inactivation method (sCIM)

Isolates no.	Isolates	sCIM inhibition zone (no growth) positive results	Scim inhibition zone (6-20) positive results	sCIM inhibition zone (22-23) intermediate results	sCIM inhibition zone \leq (25-26) negative results
2,4,5,12 & 20	<i>E.coli</i>	-	-	5	-
3,6,11,15,9 & 29	<i>E.coli</i>	-	6	-	-
8,17,24,26,28 & 30	<i>E.coli</i>	0	0	0	6
10,14,19,22 & 23	<i>E.coli</i>	5	-	-	-
Total	22	5(22.73%)	6(27.27%)	5(22.73%)	6(27.27%)

**Figure 2.** Agarose electrophoresis patterns show PCR amplified products of the *KPC* gene. Lane L: (2000 bp DNA ladder), Lane:(no. 1-5)**Figure 3.** Agarose electrophoresis patterns show PCR amplified products of the *Vim* gene. Lane L: (2000 bp DNA ladder), Lane: (no. 1-6) *Vim* gene bands of *E.coli* isolates**Figure 4.** Agarose electrophoresis patterns show PCR amplified products of *IMP* gene. Lane L: (2000 bp DNA ladder), Lane: (no. 1-5) *IMP* gene bands of *E.coli* isolates**Figure 5.** Agarose electrophoresis patterns show PCR amplified products of the *SPM* gene. Lane L: (2000 bp DNA ladder), Lane: (no. 1-4) *SPM* gene bands of *E.coli* isolates

4. Discussion

Cancer patients frequently have impaired immune systems due to chemotherapy and other treatments, which makes them vulnerable to opportunistic infections. The most frequent causes of morbidity and death in cancer patients include UTIs (16). The UTIs caused by *E. coli* strains cause morbidity in hospitalized cancer patients due to host defense impairments (1). Based on the findings of the current study, *E. coli* was the most common bacteria isolated from urinary tract infections with a prevalence rate of 53.65%.

A study performed by Munyi, Macharia (17) included samples of patients suffering from leukemic (31.2%) causative agents due to *E. coli*. Al-naimi and Abbas (18) in their study found *E. coli* in 21 (31.82%) isolates and Shrestha, Wei (19) reported that the most common organism isolated in their research was *E. coli* (58%). In addition, Islam, Akhter (20) declared that the rate of *E. coli* infection in their study was 53%. They described the design and performance of the eCIM, as a phenotypic method for distinguishing serine and metallo- β -lactamase (MBL) carbapenemases encoded by Enterobacteriaceae.

Notably, the eCIM format was created to supplement the mCIM format and requires low-cost "off-the-shelf" materials available to most clinical laboratories, even those in remote locations. The assay is also simple to perform and interpret. It is essential to distinguish between serine and metal-dependent carbapenemases for infection control, prevention, and therapeutic purposes (12). Results of the present study were consistent with those of a study performed by Sfeir, Hayden (12) which showed that 48.7% out of 75 isolates were positive for produced carbapenemase types class A+D. Moreover, 48.7% of the isolates were positive for produced carbapenemase types class A+D and class B.

In comparison, in this research, 45.3% of the isolates were negative for produced carbapenemase. The detection principles of the sCIM and the mCIM are

similar since carbapenemases can hydrolyze carbapenem (21). Nevertheless, the sCIM experiment has fewer steps and is more convenient than the mCIM (22). The Vitek[®]2 system was used in the current study to confirm antibiotic susceptibility tests of *E. coli* isolates to detect their ability to produce carbapenemase.

Healthcare-associated infections are frequently caused by Enterobacteriaceae, particularly in cancer patients. These infections respond well to the medicines known as carbapenems, frequently used to treat them. Recently, there has been an increase in resistance to antibiotics of the carbapenem class (23). The isolates that are resistant to carbapenems are linked to high morbidity and death rates, particularly those that generate the enzyme *Klebsiella pneumoniae* carbapenemase (*bla_{KPC}*) (24). The *bla_{VIM}*-type MBLs also have larger substrate specificities and a stronger affinity for carbapenems, compared to other MBLs (25).

Isolates expressing *bla_{VIM}*-type MBLs have been found all over the world. Numerous clinical, animal, environmental, and Enterobacteriaceae samples have been discovered to contain *bla_{VIM}*-type MBLs. Since then, 71 *VIM* variations have been found in various nations (26). *bla_{IMP}*-type carbapenemases are capable of hydrolyzing nearly all β -lactams. The popular *bla_{IMP}*-type carbapenemases have been found in a wide range of Enterobacteriaceae family. The *bla_{IMP}* genes are typically found on large plasmids with various replicon types or incompatibility types (27). The *bla_{IMP-1}* gene was found on a transmissible plasmid, and the enzyme was most similar to *bla_{IMP-1}* and featured the typical MBL zinc-binding motif (35.5 %) (28, 29).

The findings indicated the presence and spread of carbapenemase-producing bacteria among bacterial isolates from clinical samples in Basrah, Iraq. This is most likely due to the widespread use of antimicrobials, a selective factor in hastening the emergence of resistant strains containing these enzymes (30, 31). Moreover, resistance genes mediated by transmissible

elements, such as plasmids, transposons, and integrons, play a significant role in increasing the frequency of the spread of these enzymes via horizontal gene transfer between bacterial species (32, 33). As a result of the selective pressure imposed by these drugs, resistant strains will flourish and dominate in these establishments and enter the environment via effluent water and wastewater. The environment will serve as an emergency source for the spread of these strains, which will be added to the existing ones (32, 34).

There is a spread of more than one type of carbapenemase among the *E. coli* isolates from UTI cancer patients in Basrah Hospital. The *E. coli* that was identified in the current study had a strong capacity to produce carbapenemase enzymes against the four generations of antibiotics, including imipenem and meropenem antibiotics.

Authors' Contribution

Study concept and design: A. A. A.

Acquisition of data: S. S. M. A.

Analysis and interpretation of data: A. A. A.

Drafting of the manuscript: A. A. A. and A. A. A.

Critical revision of the manuscript for important intellectual content: S. S. M. A.

Statistical analysis: A. A. A.

Administrative, technical, and material support: A. A. A.

Ethics

The Ethics Committee of Al-Sader Teaching Hospital approved this study.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgment

This work was supported by the Department of Biology, College of Science, University of Basrah, Iraq.

References

1. Mahmoud AT, Salim MT, Ibrahem RA, Gabr A, Halby HM. Multiple drug resistance patterns in various phylogenetic groups of hospital-acquired uropathogenic *E. coli* isolated from cancer patients. *Antibiotics*. 2020;9(3):108.
2. Tigabu A, Ferede W, Belay G, Gelaw B. Prevalence of asymptomatic bacteriuria and antibiotic susceptibility patterns of bacterial isolates among cancer patients and healthy blood donors at the University of Gondar Specialized Hospital. *Int J Microbiol*. 2020;2020.
3. Flores-Mireles A, Hreha TN, Hunstad DA. Pathophysiology, treatment, and prevention of catheter-associated urinary tract infection. *Topics in spinal cord injury rehabilitation*. 2019;25(3):228-40.
4. Abd El Ghany M, Sharaf H, Al-Agamy MH, Shibl A, Hill-Cawthorne GA, Hong P-Y. Genomic characterization of NDM-1 and 5, and OXA-181 carbapenemases in uropathogenic *Escherichia coli* isolates from Riyadh, Saudi Arabia. *PloS One*. 2018;13(8):e0201613.
5. Korbel L, Howell M, Spencer JD. The clinical diagnosis and management of urinary tract infections in children and adolescents. *Paediatr Int Child Health*. 2017;37(4):273-9.
6. Cooper AL, Carter C, McLeod H, Wright M, Sritharan P, Tamber S, et al. Detection of carbapenem-resistance genes in bacteria isolated from wastewater in Ontario. *FACETS*. 2021;6(1):569-91.
7. Li J, Li C, Cai X, Shi J, Feng L, Tang K, et al. Performance of modified carbapenem inactivation method and inhibitor-based combined disk test in the detection and distinguishing of carbapenemase producing Enterobacteriaceae. *Ann Transl Med*. 2019;7(20).
8. Elbadawi HS, Elhag KM, Mahgoub E, Altayb HN, Ntoumi F, Elton L, et al. Detection and characterization of carbapenem resistant Gram-negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan. *BMC Microbiol*. 2021;21(1):1-9.
9. Forbes BA, Sahn DF, Weissfeld AS. *Diagnostic microbiology: Mosby St Louis*; 2007.
10. Prescott LM, Harley JP. *Harley Prescott: Laboratory Exercises in Microbiology, Fifth Editio*. The McGraw– Hill; 2002.
11. CLSI CLSI. *Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute Wayne, PA*; 2017.

12. Sfeir M, Hayden J, Fauntleroy K, Mazur C, Johnson J, Simner P, et al. EDTA-modified carbapenem inactivation method: a phenotypic method for detecting metallo- β -lactamase-producing Enterobacteriaceae. *J Clin Microbiol.* 2019;57(5):e01757-18.
13. Shoja S, Moosavian M, Peymani A, Tabatabaiefar MA, Rostami S, Ebrahimi N. Genotyping of carbapenem resistant *Acinetobacter baumannii* isolated from tracheal tube discharge of hospitalized patients in intensive care units, Ahvaz, Iran. *Iran J Microbiol.* 2013;5(4):315.
14. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F. Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania. *BioMed Res Int.* 2014;2014.
15. Mahmoud NE, Altayb HN, Gurashi RM. Detection of carbapenem-resistant genes in *Escherichia coli* isolated from drinking water in Khartoum, Sudan. *J Environ Public Health.* 2020;2020.
16. Ogefere HO, Omoregie R, Iriah SE. Urinary tract infection among cancer patients in Benin City, Nigeria. *Int J Biomed Health Sci.* 2021;7(3).
17. Munyi S, Macharia W, Alwar A, Njeru EK. Screening for urinary tract infection in children with cancer. *East African medical journal.* 1998;75(5):264-7.
18. Al-naimi IA, Abbas MA. Research article recurrent urinary tract infections in Iraqi leukemic patients. *Int J.* 2016;4(3):1433-9.
19. Shrestha G, Wei X, Hann K, Soe KT, Satyanarayana S, Siwakoti B, et al. Bacterial profile and antibiotic resistance among cancer patients with urinary tract infection in a national tertiary cancer hospital of Nepal. *Trop Med Infect Dis.* 2021;6(2):49.
20. Islam MR, Akhter F, Khatun N, Rahman M. Bacterial Causes of Infections and Their Antimicrobial Sensitivity Pattern in Cancer Patients. 2021.
21. Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. *J Clin Microbiol.* 2017;55(8):2321-33.
22. Jing X, Zhou H, Min X, Zhang X, Yang Q, Du S, et al. The simplified carbapenem inactivation method (sCIM) for simple and accurate detection of carbapenemase-producing gram-negative bacilli. *Front Microbiol.* 2018;9:2391.
23. Freire M, Pierrotti L, Ibrahim K, Magri A, Bonazzi P, Hajar L, et al. Infection with *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Klebsiella pneumoniae* in cancer patients. *Eur J Clin Microbiol Infect Dis.* 2015;34(2):277-86.
24. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence.* 2017;8(4):460-9.
25. Carugati M, Piazza A, Peri A, Cariani L, Brilli M, Girelli D, et al. Fatal respiratory infection due to ST308 VIM-1-producing *Pseudomonas aeruginosa* in a lung transplant recipient: case report and review of the literature. *BMC Infect Dis.* 2020;20(1):1-7.
26. Hishinuma T, Uchida H, Tohya M, Shimojima M, Tada T, Kirikae T. Emergence and spread of VIM-type metallo- β -lactamase-producing *Pseudomonas aeruginosa* clinical isolates in Japan. *J Glob Antimicrob Resist.* 2020;23:265-8.
27. Lai K, Ma Y, Guo L, An J, Ye L, Yang J. Molecular characterization of clinical IMP-producing *Klebsiella pneumoniae* isolates from a Chinese Tertiary Hospital. *Ann Clin Microbiol Antimicrob.* 2017;16(1):1-5.
28. Chaves L, Tomich LM, Salomão M, Leite GC, Ramos J, Martins RR, et al. High mortality of bloodstream infection outbreak caused by carbapenem-resistant *P. aeruginosa* producing SPM-1 in a bone marrow transplant unit. *J Med Microbiol.* 2017;66(12):1722-9.
29. Nascimento AP, Ortiz MF, Martins WM, Morais GL, Fehlberg LC, Almeida LG, et al. Intracolonial genome stability of the metallo- β -lactamase SPM-1-producing *Pseudomonas aeruginosa* ST277, an endemic clone disseminated in Brazilian hospitals. *Front Microbiol.* 2016;7:1946.
30. Ali SB, Perdawood D, Abdulrahman R, Al Farraj DA, Alkubaisi NA. Vitamin D deficiency as a risk factor for urinary tract infection in women at reproductive age. *Saudi Journal of Biological Sciences.* 2020;27(11):2942-7.
31. Bonardi S, Pitino R. Carbapenemase-producing bacteria in food-producing animals, wildlife and environment: A challenge for human health. *Ital J Food Saf.* 2019;8(2).
32. Al-Hasso M. Molecular detection of carbapenemases in Gram negative bacilli isolated from different sources in Mosul city, Iraq. *Kuwait J Sci.* 2021.
33. Le Terrier C, Masseron A, Uwaezuoke NS, Edwin CP, Ekuma AE, Olugbeminiyi F, et al. Wide spread of carbapenemase-producing bacterial isolates in a Nigerian environment. *J Glob Antimicrob Resist.* 2020;21:321-3.
34. Hamza E, Dorgham SM, Hamza DA. Carbapenemase-producing *Klebsiella pneumoniae* in broiler poultry farming in Egypt. *J Glob Antimicrob Resist.* 2016;7:8-10.